[en] Objective: To evaluate the functional outcome, predicting response and toxicity of CT- guided permanent implanted ¹²⁵I seed brachytherapy for metastatic cancers in vertebrae. Methods: Forty three vertebrae with metastatic cancer were treated by CT-guided percutaneous permanent implanted ¹²⁵I seed brachytherapy in 15 patients. There were 8 male and 7 female patients with average age of 54.6 years and 2 to 5 vertebrae involved in this group. According to the size of tumor, the optimal activity and quantity of seeds were calculated by TPS and correlative formula. ¹²⁵I seeds were implanted percutaneous puncture under CT- guidance with coaxial needles to pass the normal osseous tissue for approaching the lesions including 3 routes of pedicular, lateral and anterior ways. The distance between seeds and posterior border of vertebral body was over 3 mm (3-10 mm). Permanent ¹²⁵I seed implantation brachytherapy for paraspinal metastatic lesions were also taken place. Results: Mean follow-up time was 12.3 months (range 3-30 months) and outcome was evaluated clinically and radiographically in 10 of 15 procedures, with 5 only on clinical data. No new pain occurred at 11 sites with no previous complaint. The pain was completely controlled at 18/32 sites, partial control at 14/32 sites. No complications correlated to the radiotherapy damage of nerve and spinal cord were found. Conclusion: The procedure of CT-guided permanent implanted ¹²⁵I seeds brachytherapy for vertebral metastatic cancers is a safe effective and minimal invasive method with few complications. It is beneficial not only for pretherapeutic metastasis but also for recurrent tumors after radiotherapy; bearing rather high tolerance and safety. (authors)